An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes (CAPTURE-IO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03811288|
Recruitment Status : Completed
First Posted : January 22, 2019
Last Update Posted : June 9, 2020
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus, Type 2||Other: No treatment given|
|Study Type :||Observational|
|Actual Enrollment :||7548 participants|
|Official Title:||A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes - an International Observation|
|Actual Study Start Date :||December 10, 2018|
|Actual Primary Completion Date :||September 30, 2019|
|Actual Study Completion Date :||September 30, 2019|
Participants with type 2 diabetes mellitus (T2DM)
T2DM patients being managed in both primary and specialist care in 10 selected countries.
Other: No treatment given
No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
- Participants with a history of established cardiovascular disease (CVD) [ Time Frame: Day 1 ]Participants having a history of established CVD, i.e. who have been diagnosed with any one of the following listed conditions (yes/no): Cerebrovascular disease, cardiovascular disease, symptomatic heart failure, asymptomatic heart failure, hospitalisation for heart failure, cardiac arrhythmia, aortic disease, peripheral artery disease or carotid artery disease.
- Participants with high risk of CVD according to the risk engine from the United Kingdom Prospective Diabetes Study (UKPDS) [ Time Frame: Day 1 ]Percentage of participants (yes/no). High risk: more than 20 percent over 10 years.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03811288
|Study Director:||Clinical Reporting Anchor and Disclosure (1452)||Novo Nordisk A/S|